Literature DB >> 22865249

Fusion protein strategy to increase expression and solubility of hypervariable region of VP2 protein of infectious bursal disease virus in Escherichia coli.

Sahar Sadat Sedighzadeh1, Mehdi Shamsara, Azar Shahpiri.   

Abstract

Infectious bursal disease is one of the most important viral diseases in the young chickens. VP2 protein is the major host protective immunogen of the virus. A hypervariable region is present in VP2 protein (hvVP2) that contains immunodominant epitops. The high hydrophobicity of hvVP2 region causes protein aggregation in Escherichia coli (E. coli). The objective of the present study was to improve the expression and the solubility of the hvVP2 protein in E. coli. The effects of fusion partners on the solubility of hvVP2 protein were studied. The protein was expressed in forms of unfused and N-terminally fused to GST and NusA. The results showed that the unfused hvVP2 protein was expressed in very low level. But, N-terminally fused hvVP2 protein to GST (glutathione-S-transferase) and NusA (N utilization substance A) showed significantly enhanced protein expression. The fusion of GST and hvVP2 was produced in aggregated form while in the presence of NusA, the hvVP2 protein was expressed in a soluble form. The NusA-hvVP2 protein was detected by a neutralizing monoclonal antibody, 1A6, in antigen-capture ELISA. In conclusion, the NusA protein is a suitable fusion partner to improve expression and solubility of the hvVP2 protein in E. coli.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22865249     DOI: 10.1007/s10930-012-9437-2

Source DB:  PubMed          Journal:  Protein J        ISSN: 1572-3887            Impact factor:   2.371


  26 in total

1.  Properties of RNA polymerase activity associated with infectious bursal disease virus and characterization of its reaction products.

Authors:  U Spies; H Müller; H Becht
Journal:  Virus Res       Date:  1987-08       Impact factor: 3.303

2.  Requirement for the carboxyl-terminal domain of Saccharomyces cerevisiae carbamoyl-phosphate synthetase.

Authors:  A L Lim; S G Powers-Lee
Journal:  J Biol Chem       Date:  1996-05-10       Impact factor: 5.157

3.  Cloning and expression of the VP2 gene of an infectious bursal disease virus.

Authors:  L Yu; A K Song; A B Zhang; R Deng
Journal:  Avian Dis       Date:  2000 Jan-Mar       Impact factor: 1.577

4.  Cloning and nucleotide analysis of the vp2 gene of a very virulent infectious bursal disease virus isolate from Iran.

Authors:  M Shamsara; S A Ghorashi; G Ahmadian
Journal:  Acta Virol       Date:  2006       Impact factor: 1.162

5.  Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase.

Authors:  D B Smith; K S Johnson
Journal:  Gene       Date:  1988-07-15       Impact factor: 3.688

6.  Isolation and characterization of a very virulent Infectious bursal disease virus from turkey.

Authors:  J Razmyar; S M Peighambari
Journal:  Acta Virol       Date:  2009       Impact factor: 1.162

7.  Pathogenesis of highly virulent infectious bursal disease virus infection in intact and bursectomized chickens.

Authors:  M Hiraga; T Nunoya; Y Otaki; M Tajima; T Saito; T Nakamura
Journal:  J Vet Med Sci       Date:  1994-12       Impact factor: 1.267

8.  Comparative studies on structural and antigenic properties of two serotypes of infectious bursal disease virus.

Authors:  H Becht; H Müller; H K Müller
Journal:  J Gen Virol       Date:  1988-03       Impact factor: 3.891

9.  The characterization and molecular cloning of the double-stranded RNA genome of an Australian strain of infectious bursal disease virus.

Authors:  A A Azad; S A Barrett; K J Fahey
Journal:  Virology       Date:  1985-05       Impact factor: 3.616

10.  Infectious bursal disease subunit vaccination.

Authors:  Pedro Villegas; M Hamoud; L B Purvis; F Perozo
Journal:  Avian Dis       Date:  2008-12       Impact factor: 1.577

View more
  1 in total

1.  Modification in media composition to obtain secretory production of STxB-based vaccines using Escherichia coli.

Authors:  Mohammad Sadraeian; Mohammad Bagher Ghoshoon; Milad Mohkam; Zeinab Karimi; Sara Rasoul-Amini; Younes Ghasemi
Journal:  Virol Sin       Date:  2013-01-17       Impact factor: 4.327

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.